Hosted on MSN25m
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay
The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...
Actuate Therapeutics To Participate In Upcoming Investor Conferences In February
BIO CEO & Investor conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...